Jaap-Jan Boelens, MD, PhD
Pediatric Hematologist-Oncologist & Bone Marrow Transplant Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Cord Blood-Derived Cell Therapies, Rare Pediatric Blood Diseases, Lysosomal Storage Diseases, Immune-Reconstitution, and Pharmaco-Kinetics/Dynamics
About Me
- Chief, Pediatric Transplant and Cellular Therapy Service (TCT)
- Richard J. O’Reilly Chair in Honor of Kevin Zoltan Merszei
I am a pediatric hematologic oncologist and Chief of the Pediatric Transplant and Cellular Therapy Service (TCT). I specialize in bone marrow and cord blood transplantation to treat blood diseases in children and young adults. I have particular expertise caring for people with rare diseases, such as lysosomal storage disorders like Hurler’s disease and leukodystrophies like metachromatic leukodystrophy, adrenoleukodystrophy, and Krabbe disease. I am also part of a dedicated team of experts working to develop new treatments for our young patients. At MSK Kids, our goal is to better control children’s disease while improving their well-being, as well as that of their families.
Read more
Before coming to Memorial Sloan Kettering in 2018, I spent a decade developing an umbilical cord blood transplant program in the Netherlands that is now the largest in Europe. Cord blood transplants are a promising treatment for people who don’t have a suitable bone marrow match. I am continuing to build on this work by looking for ways to combine transplants with new cellular therapies. My goal is to raise the chance of eliminating disease while having less of an impact on my patients’ quality of life.
In my lab research, I feel passionate about finding better ways to help young people with blood disorders lead longer, healthier lives. We are developing advanced therapies made from cord blood that will target blood disorders at the cellular level. We are also creating mathematical models that can help us predict how a young person’s immune system will respond to these treatments. I want to take discoveries out of the lab and to the bedside to help my patients.
When I meet with patients and their families, they are often dealing with a lot of uncertainty. They have received a life-changing diagnosis and face questions about treatment, possible complications, the chance of responding to treatment, and how this experience will affect their family. I guide my patients and their families through these unknowns by giving them the time and space they need to ask me questions and process the information they hear. I try to be completely open and honest so my patients feel heard, respected, and cared for. We spend as much time together as needed to make sure this happens.
A pediatric hematologist-oncologist is a doctor who treats cancers of the blood in children and adolescents. This doctor is a hematologist (HEE-muh-TAH-loh-jist) who diagnoses and treats blood disorders. They also are an oncologist (cancer doctor).
A bone marrow transplant specialist is a doctor with special training in bone marrow transplants.
My Specialties
- Cord Blood-Derived Cell Therapies, Rare Pediatric Blood Diseases, Lysosomal Storage Diseases, Immune-Reconstitution, and Pharmaco-Kinetics/Dynamics
Education
- MD, University Medical Center Utrecht, Netherlands
- PhD, University of Amsterdam/Academic Medical Center
Residencies
- Pediatrics - Leiden University Medical Center/Juliana Kinderziekenhuis, Leiden, The Hague, Netherlands
Awards and Honors
- Swammerdam Prize for Innovation in Cell Therapy/Oncology, The Dutch Society of Hematology (2015)
Fellowships
- Immunology – University Medical Center Utrecht, Netherlands
- Oncology – Erasmus University Medical Center, Netherlands
Board Certifications
- Pediatrics
- Oncology (Netherlands)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Boelens sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Boelens
- A Phase I/II Study of ECT-001-Expanded Cord Blood Transplants in Young People with Bone Marrow Cancers
- A Phase I/II Study of SMART101 in Children and Adults with Acute Leukemia Who Receive a T-Cell Depleted Stem Cell Transplant from a Donor
- Clinical Trials Co-Investigated by Dr. Boelens
- A Phase 2 Study Assessing Treatment for Inflammation Before a Stem Cell Transplant in People with Immune and Autoinflammatory Conditions
- A Phase 2 Study of Emapalumab for Pediatric Aplastic Anemia
Read more
- A Phase 3 Study of Itolizumab plus Corticosteroids to Treat Acute Graft-Versus-Host Disease
- A Phase I Study of AMG 191 Given Before Transplant to Patients with Severe Combined Immunodeficiency (SCID)
- A Phase I Study of UCART22 CAR T-Cell Therapy in Children and Young Adults with Recurrent or Persistent B-Cell Acute Lymphoblastic Leukemia
- A Phase II Study Assessing a Second Infusion of Tisagenlecleucel CAR T-Cell Therapy in Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia
- A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders
- A Study Using Immune Suppression Prior to Stem Cell Transplant for Children and Adults with Sickle Cell Disease or Beta-Thalassemia
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, Belitser SV, Bredius RG, Raymakers RA, Knibbe CA, Minnema MC, van Kesteren C, Kuball J, Boelens JJ. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017 Apr;4(4):e183-e191. doi: 10.1016/S2352-3026(17)30029-7
Admiraal R, de Koning C, Lindemans CA, Bierings MB, Wensing AM, Versluys AB, Wolfs TF, Nierkens S, Boelens JJ. Viral Reactivations and Associated Outcomes in Context of Immune Reconstitution after Pediatric Hematopoietic Cell Transplantation. J Allergy Clin Immunol. 2017 Apr 6. pii: S0091-6749(17)30571-7. doi: 10.1016/j.jaci.2016.12.992.
Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluys AB, Nierkens S, Boelens JJ. Excellent T-cell reconstitution and survival provided ATG exposure is low or absent after pediatric cord blood transplantation. Blood 2016 Oct 4. pii: blood-2016-06-721936. PubMed PMID: 27702800.
Read more
Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, van Tol MJ, Knibbe CA, Bredius RG, Boelens JJ. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamics cohort analysis. Lancet Haematol. 2015;2(5):e194-203
Bartelink I, Lalmohamed A, Elisabeth M van Reij, Christopher C Dvorak,Rada M Savic, Juliette Zwaveling, Robbert G Bredius, Antoine C Egberts, Marc Bierings, Peter Shaw, Christa E Nath, George Hempel, Marc Ansari,Maja Krajinovic, Yves Theoret, Michel Duval, MD; Ron J Keizer, PhD, Henrique Bittencourt, Moustapha Hassan, Tayfun Güng.r, Robert F Wynn, Paul Veys, Geoff D Cuvelier, Sarah Marktel, Robert Chiesa, Morton J Cowan, Mary A Slatter, Melisa K Stricherz, Cathryn Jennissen, Morris Kletzel, Janel R Long-Boyle, Jaap J Boelens, Association of Busulfan exposure with survival and toxicity after HCT in Children and Young Adults: a Multicenter Retrospective Cohort Analysis Lancet Hematology 2016; 10.1016/S2352-3026(16)30114-4.
Spel L, Boelens JJ, van der Steen DM et al, Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget. 2015 Nov 3;6(34):35770-81.
Aldenhoven M, Wynn RF, Orchard PJ, O’Meara A, Veys P, Fischer A, Valayannopoulos V, Neven B, Rovelli A, Prasad VK, Tolar J, Allewelt H, Jones SA, Parini R, Renard M, Bordon V, Wulffraat NM, de Koning TJ, Shapiro EG, Kurtzberg J, Boelens JJ. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 2015 Mar 26;125(13):2164-72.
Visit PubMed for a full listing of Dr. Boelens’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jaap-Jan Boelens discloses the following relationships and financial interests:
-
Advanced Clinical
Professional Services and Activities -
Immusoft
Professional Services and Activities -
Merck & Co Inc.
Professional Services and Activities
-
Sanofi US Services Inc.
Professional Services and Activities -
Smart Immune SAS
Professional Services and Activities -
Sobi - Swedish Orphan Biovitrum AB
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].